JPWO2019246264A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019246264A5
JPWO2019246264A5 JP2020570916A JP2020570916A JPWO2019246264A5 JP WO2019246264 A5 JPWO2019246264 A5 JP WO2019246264A5 JP 2020570916 A JP2020570916 A JP 2020570916A JP 2020570916 A JP2020570916 A JP 2020570916A JP WO2019246264 A5 JPWO2019246264 A5 JP WO2019246264A5
Authority
JP
Japan
Prior art keywords
mer
pharmaceutical composition
chondroitin sulfate
composition according
skeleton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570916A
Other languages
Japanese (ja)
Other versions
JP2021528421A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037993 external-priority patent/WO2019246264A1/en
Publication of JP2021528421A publication Critical patent/JP2021528421A/en
Publication of JPWO2019246264A5 publication Critical patent/JPWO2019246264A5/ja
Pending legal-status Critical Current

Links

Claims (5)

ヒストン毒性及び/又は敗血症の治療に使用するための医薬組成物であって、１又はそれ以上のコンドロイチン硫酸化合物及び薬学的に許容される担体若しくはアジュバントを含む医薬組成物。 A pharmaceutical composition for use in the treatment of histone toxicity and / or sepsis, comprising one or more chondroitin sulfate compounds and a pharmaceutically acceptable carrier or adjuvant . 前記コンドロイチン硫酸化合物が、ＣＳ骨格、ＣＳ－Ａ、ＣＳ－Ｅ、ＣＳ－Ｃ及び／又はこれらの組み合わせを含む、請求項１に記載の医薬組成物。 The pharmaceutical composition according to claim 1 , wherein the chondroitin sulfate compound comprises a CS skeleton, CS-A, CS-E, CS-C and / or a combination thereof. 前記コンドロイチン硫酸化合物が、コンドロイチン硫酸骨格 19-mer（19量体）、ＣＳ－Ａ 19-mer（19量体）、ＣＳ－Ｃ 19-mer（19量体）、ＣＳ－Ｅ 19-mer（19量体）、ＣＳ骨格13-mer（13量体）、ＣＳ－Ａ 13-mer（13量体）、ＣＳ－Ｃ 13-mer（13量体）、ＣＳ－Ｅ 13-mer（13量体）及び/又はこれらの組み合わせから成る、請求項１又は２に記載の医薬組成物。 The chondroitin sulfate compound is chondroitin sulfate skeleton 19-mer (19-mer), CS-A 19-mer (19-mer), CS-C 19-mer (19-mer), CS-E 19-mer (19). (Medium), CS skeleton 13-mer (13-mer), CS-A 13-mer (13-mer), CS-C 13-mer (13-mer), CS-E 13-mer (13-mer) The pharmaceutical composition according to claim 1 or 2 , which comprises and / or a combination thereof. 前記コンドロイチン硫酸化合物が、下記構造のうちの１又はそれ以上を含む、請求項１～３のいずれか一項に記載の医薬組成物。
Figure 2019246264000001
Figure 2019246264000002
 （式中、Ｒは、水素原子、アルキル、置換アルキル、アリール、及び置換アリールからなる群から選択され、ｎは１、２、３、４、５、６、７又は８を表す。） The pharmaceutical composition according to any one of claims 1 to 3 , wherein the chondroitin sulfate compound contains one or more of the following structures.
Figure 2019246264000001
Figure 2019246264000002
 (In the formula, R is selected from the group consisting of hydrogen atom, alkyl, substituted alkyl, aryl, and substituted aryl , and n represents 1, 2, 3, 4, 5, 6, 7 or 8. ) 前記Ｒが、－ＣＨThe R is -CH ３3 、－ＣＨ, -CH ２2 ＣＨCH ３3 、又はｐ－ニトロフェニル基である、請求項４に記載の医薬組成物。, Or the pharmaceutical composition according to claim 4, which is a p-nitrophenyl group.
JP2020570916A 2018-06-20 2019-06-19 Cell protection methods and compositions Pending JP2021528421A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687540P 2018-06-20 2018-06-20
US62/687,540 2018-06-20
PCT/US2019/037993 WO2019246264A1 (en) 2018-06-20 2019-06-19 Cell protective methods and compositions

Publications (2)

Publication Number Publication Date
JP2021528421A JP2021528421A (en) 2021-10-21
JPWO2019246264A5 true JPWO2019246264A5 (en) 2022-06-27

Family

ID=68984366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570916A Pending JP2021528421A (en) 2018-06-20 2019-06-19 Cell protection methods and compositions

Country Status (5)

Country Link
US (2) US11633424B2 (en)
EP (1) EP3810152A4 (en)
JP (1) JP2021528421A (en)
CN (1) CN112437667B (en)
WO (1) WO2019246264A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
WO2019010216A1 (en) * 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
CN111601603A (en) 2017-11-03 2020-08-28 北卡罗来纳大学查珀尔希尔分校 Sulfated oligosaccharides with anti-inflammatory activity

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (en) 1987-11-06 1992-03-10 Opocrin Spa EPARAN SULPHATE CHARACTERIZED BY HIGH ANTI-THROMBOTIC ACTIVITY, HIGH BIOAVAILABILITY, ABSENCE OF ANTI-AGULANT ACTIVITY; ITS PROCESS OF EXTRACTION FROM ORGANS AND FABRICS AND RELATED PHARMACEUTICAL COMPOSITIONS
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (en) 1989-04-24 1990-11-20 Harvard College PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (en) 1992-04-17 1996-03-28 Alfa Wassermann Spa SEMI-SYNTHETIC GLYCOSAMINOGLICANS WITH EPARINIC OR EPARANIC STRUCTURE MODIFIED IN POSITION 2 OF ALPHA-L-IDURONIC-2-0-SULPHATE ACID
JP3818676B2 (en) 1994-07-22 2006-09-06 生化学工業株式会社 Heparan sulfate 6-O-sulfotransferase
IT1271057B (en) 1994-11-04 1997-05-26 Inalco Spa POLYSACCHARIDES HAVING A HIGH CONTENT OF HYDURONIC ACID
JP3672359B2 (en) 1995-07-24 2005-07-20 生化学工業株式会社 Heparan sulfate 2-O-sulfotransferase
US20010006635A1 (en) 1995-09-29 2001-07-05 D. Clark Bennett Use of heparinase to decrease inflammatory responses
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
ATE453655T1 (en) 2000-07-07 2010-01-15 Seikagaku Kogyo Co Ltd HYALURONIC ACID OLIGOSACCHARIDE FRACTIONS AND MEDICATIONS CONTAINING THEM
JP2005507640A (en) 2001-03-28 2005-03-24 マサチューセッツ・インスティチュート・オブ・テクノロジー Method for 6-O sulfation of glucosaminyl and 6-O sulfated polysaccharide preparation
WO2002089742A2 (en) 2001-05-08 2002-11-14 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase and methods of making and using same
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
AU2003247808A1 (en) 2002-07-05 2004-01-23 Anders Malmstrom Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
AU2003262794A1 (en) 2002-08-23 2004-03-11 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
ATE502062T1 (en) 2003-10-24 2011-04-15 3M Innovative Properties Co AQUEOUS DISPERSIONS OF POLYTETRAFLUORETHYLENE PARTICLES
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
JP2008500372A (en) * 2004-05-26 2008-01-10 カリフォルニア インスティテュート オブ テクノロジー Small molecule stimulators of neuronal growth
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
EP1885865A4 (en) 2005-05-12 2010-12-22 Univ North Carolina Enzymatic synthesis of sulfated polysaccharides
CA2652205A1 (en) 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
WO2009014715A2 (en) 2007-07-23 2009-01-29 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
UA105781C2 (en) * 2009-02-02 2014-06-25 Оцука Фармасьютікал Ко., Лтд. Low-molecular polysulfated hyaluronic acid derivative and therapeutic agent comprising thereof
US20120064044A1 (en) 2009-04-09 2012-03-15 Thomas Michael Egan Methods of treating edema related to ischemia-reperfusion
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
CN103402526B (en) * 2010-12-01 2016-01-20 澳大利亚国立大学 Histone suppresses
WO2012088416A2 (en) 2010-12-23 2012-06-28 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
EP3011043B1 (en) 2013-06-17 2022-05-11 The University of North Carolina At Chapel Hill Reversible heparin molecules
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
WO2019010216A1 (en) * 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
CN111601603A (en) 2017-11-03 2020-08-28 北卡罗来纳大学查珀尔希尔分校 Sulfated oligosaccharides with anti-inflammatory activity
CN114980904A (en) 2019-11-13 2022-08-30 北卡罗来纳大学查珀尔希尔分校 Effect of Heparan Sulfate (HS) oligosaccharides on liver ischemia reperfusion injury

Similar Documents

Publication Publication Date Title
JP2008511601A5 (en)
JP2006528643A5 (en)
JP2008510828A5 (en)
JP2008508360A5 (en)
KR970025611A (en) Substituted sulfonimidamides, methods for their preparation, their use as pharmaceuticals or diagnostic agents, and pharmaceuticals containing the same
EP0325245A1 (en) Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use
JP2005517643A5 (en)
JP2006523241A5 (en)
JPWO2019246264A5 (en)
KR880011082A (en) β-amino ethyl-substituted phenyl compounds and their pharmaceutically acceptable salts and amides
RU94019411A (en) KHINUK LIDINA ETHERS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
JP2021091670A5 (en)
JP2005526149A5 (en)
RU2007124202A (en) NEW COMPOUNDS HAVING ANTIKOAGULANT FUNCTION, PHARMACEUTICAL COMPANIES THERE ON THEM FOR THE TREATMENT OF THROMBOTIC CONDITIONS AND PLASMA SUBSTITUTING SOLUTION FOR HYPERPERULOGEN CORRECTION
JP2006517932A5 (en)
RU2211837C2 (en) Tricyclic condensed heterocyclic compounds, method for their preparing (variants) and pharmaceutical composition
EP2291346A2 (en) Therapeutic substituted cyclopentanes
JPWO2022030606A5 (en)
US6482990B1 (en) Prostaglandin E analogues
KR970026597A (en) Sulfonylamino-substituted benzoylguanidines, methods for their preparation, their use as medicaments or diagnostic auxiliaries and medicaments containing same
RU97113146A (en) SUBSTITUTED INDANYLIDINACETHYLGUANIDINES, METHOD FOR PRODUCING THEM, USE AS MEDICINES OR DIAGNOSTIC MEDICINES AND MEDICINES CONTAINING THESE COMPOUNDS
JP2005506324A5 (en)
JPS5834471B2 (en) chemical compounds
JPWO2021097345A5 (en)
JP2007532576A5 (en)